Recurrent Cardiac Constriction after Implantation of an Expanded Polytetrafluoroethylene Surgical Membrane

Paul-Cătălin Puiu1,2 Matthias Siepe1,2 Wolfgang Zeh2,3 Emmanuel Zimmer1,2

1 Department of Cardiovascular Surgery, Universitäts-Herzzentrum Freiburg Bad Krozingen, Bad Krozingen, Baden Württemberg, Germany
2 Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany
3 Department of Cardiology, Universitäts-Herzzentrum Freiburg Bad Krozingen, Bad Krozingen, Baden-Württemberg, Germany

Thorac Cardiovasc Surg Rep 2022;11:e1–e3.

Address for correspondence Paul-Cătălin Puiu, MDs, Department of Cardiovascular Surgery, Universitäts-Herzzentrum Freiburg Bad Krozingen, Südring 15, Bad Krozingen, Baden Württemberg 79189, Germany (e-mail: puiupaulcatalin@gmail.com).

Abstract
One of the challenges compounding the complexity of reoperative cardiac surgery is the surgical adhesion, which can be responsible for adverse intraoperative events. Implantation of a substitute neo-pericardium has become a frequently used solution, with currently rising numbers of reoperations. We report the case of a 38-year-old man who developed recurrent delayed cardiac constriction following the implantation of an expanded polytetrafluoroethylene neo-pericardium. Careful preoperative planning is recommended to plan the optimal method of pericardioplasty, taking into account the pros and cons of each available material.

Keywords
► pericardium
► cardiac surgery
► surgery

Introduction
One of the challenges compounding the complexity of reoperative cardiac surgery are the surgical adhesions, which can be responsible for adverse intraoperative events.1 Closure of the native pericardium is not always possible and in such situations implantation of a substitute neo-pericardium has become a frequently used solution for avoiding injuries to the heart and great vessels, with currently rising numbers of reoperations.1,2

The safety and efficacy of the Gore-Tex surgical membrane (SM) have been already reported. Scanning electron microscopic examination demonstrated neither cellular ingrowth nor immunocompetent cellular elements.3,4 The patients reoperated had no adhesions and the dissection was reported to be easier.

In this report we present a case of recurrent delayed cardiac constriction after implantation of GORE PRECLUDE Pericardial Membrane SM.

Clinical Summary
A 38-year-old man (187 cm, 115 kg, body mass index 32.9 kg/m²) with a history of hypertension, hypercholesterolemia, smoking, and constrictive pericarditis was admitted with progressive dyspnea, fatigue, and peripheral congestion. Echocardiography showed a moderate aortic insufficiency and a bicuspid Sievers type 1 aortic valve. Computed tomographic angiography revealed an ascending aortic aneurysm with a diameter of 48 mm and a thickened pericardium. Coronary angiography results were normal.
Echocardiography and diagnostic hemodynamic cardiac catheterization also confirmed the diagnosis of constrictive pericarditis. Valve sparing aortic root replacement (David procedure) with leaflet repair, ascending aorta replacement, and pericardiectomy was indicated. Informed consent of the patient was obtained.

After median sternotomy, a thickened (0.5–1 cm) leather-like pericardium with significant adhesions was observed. A “from phrenic to phrenic” and diaphragmatic pericardiectomy was performed. After successfully performing the above-mentioned operative steps, an expanded polytetrafluoroethylene (e-PTFE) neo-pericardium (GORE PRECLUDE) was implanted (Fig. 1). Postoperatively, after an uneventful recovery, the patient was discharged asymptomatic after 7 days. Transthoracic echocardiography at discharge showed an ejection fraction of 62%, no sign of constrictive pericarditis, and a good surgical outcome without any residual aortic insufficiency.

Two years and 2 months after the initial operation the patient was readmitted with progressive dyspnea and marked limitation of ordinary activity (New York Heart Association III). A diagnosis was made: echocardiography and diagnostic hemodynamic cardiac catheterization (re-)confirmed the diagnosis of constriction. After median re-sternotomy the neo-pericardium was excised, under which a layer of granulation tissue of approximately 5 mm assembling a foreign body reaction was observed under the whole length of the e-PTFE patch (Fig. 2). The layer was completely excised and biopsy samples were sent to the pathology laboratory. The result reported a pattern of chronic inflammation and nodular aggregation of lymphocytes, confirming a foreign-body granulomatous reaction. After the surgery the patient recovered uneventfully and was discharged after 6 days. Laboratory data before and after the operations are presented in Table 1.

Discussion

Constrictive pericarditis limits the diastolic ventricular filling of the heart with the resulting pathophysiological cascade of reduced cardiac output and congestion. Surgical pericardiectomy can restore the normal physiology, provided that there is no cardiomyopathic component. It has been shown that radical pericardiectomy is superior to conventional in terms of long-term mortality, right ventricular systolic pressure, and tricuspid regurgitation.

Surgical implantation of a neo-pericardium in patients undergoing cardiac surgery and having a high probability of reoperation is recommended to avoid adverse intra-operative events during the eventual reoperation. Pericardial reconstruction is also indicated after pneumonectomy with pericardiectomy or pericardiectomy as prophylaxis of heart herniation, a condition associated with a very high mortality because of the torsion of the atrophicaval junction and great vessels. Therapeutic reconstruction can also be performed for symptomatic congenital pericardial agenesia.

The pericardium can be reconstructed using biological (heterologous or autologous) or synthetic material, each having their pros and cons. The bovine pericardial patch as heterologous biological material has been demonstrated to be a strong and versatile surgical material but can elicit a hypersensitivity reaction. On the other hand, autologous material such as pleural or pericardial fat flap is well tolerated and infection-resistant but not strong enough. Fascia lata flaps have the disadvantage of requiring a secondary incision and operative field. Synthetic meshes have become the material of choice and the Gore-Tex SM emerged as an optimal option for pericardioplasty.

In this case report, we present a patient who developed recurrent delayed cardiac constriction after implantation of an e-PTFE SM needing a reoperation for relieving the constrictive component. The pathology report indicated a foreign-body granulomatous reaction. Sakuma and colleagues demonstrated in an experimental study that e-PTFE sheets can cause extensive inflammatory reaction. Macrophages are the main cell type implicated in the inflammatory reaction against implanted materials and based on the available evidence, the steps of the inflammatory response leading to granulation tissue formation are the following: protein adsorption on the surface of the implant, coagulation cascade initiation, monocyte adhesion, macrophage activation, and foreign-body giant cell formation.
materials may diminish the secretion of cytokines and immune activation but they are currently in in vitro phase.

**Conclusion**

We report a case of recurrent delayed cardiac constriction with the confirmed morphological correlate of foreign-body reaction following the implantation of a polytetrafluoroethylene (e-PTFE) neo-pericardium (GORE PRECLUDE Pericardial Membrane) SM. A highly differentiated algorithm and a careful preoperative review of indication is recommended to plan the optimal method of pericardioplasty, taking into account the pros and cons of each available material.

**Funding**

No funding was received.

**Conflict of Interests**

None.

**References**


---

**Table 1** Laboratory data

<table>
<thead>
<tr>
<th></th>
<th>Before the first surgery</th>
<th>After the first surgery</th>
<th>Before the second surgery</th>
<th>After the second surgery</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRP (0.0–0.5 mg/dL)</td>
<td>0.7</td>
<td>11.4</td>
<td>0.8</td>
<td>6.8</td>
</tr>
<tr>
<td>White cell count 4,600–10,200/µL</td>
<td>9,540</td>
<td>11,810</td>
<td>9,060</td>
<td>16,470</td>
</tr>
<tr>
<td>Neutrophils, % 51.0–74.0%</td>
<td></td>
<td>58.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lymphocytes, % 25.0–45.0%</td>
<td></td>
<td>16.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monocytes, % 0–14.0%</td>
<td></td>
<td>10.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eosinophils, % 1.0–4.0%</td>
<td></td>
<td>13.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Basophils, % 0–1.0%</td>
<td></td>
<td>0.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Immature granulocytes %</td>
<td></td>
<td>1.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thrombocytes 150–400 10^3/µL</td>
<td>265</td>
<td>432</td>
<td>218</td>
<td>125</td>
</tr>
<tr>
<td>Hemoglobin 14–18 g/dL</td>
<td>14.5</td>
<td>10.4</td>
<td>13.5</td>
<td>11.8</td>
</tr>
</tbody>
</table>

Abbreviation: CRP, C-reactive protein.